Tirzepatide sabon magani ne wanda ke wakiltar babban ci gaba a cikin jiyya na nau'in ciwon sukari na 2 da kiba. Shine agonist dual na farko na masu karɓar insulinotropic polypeptide (GIP) da glucagon-like peptide-1 (GLP-1). Wannan keɓantaccen tsarin aiki ya keɓe shi daga hanyoyin kwantar da hankali da ke akwai kuma yana ba da tasiri mai ƙarfi akan sarrafa glucose na jini da rage nauyi.
Ta hanyar kunna masu karɓar GIP da GLP-1, Tirzepatide yana haɓaka haɓakar insulin da hankali, yana rage ƙwayar glucagon, yana rage ɓarnawar ciki, kuma yana rage ci.
An gudanar da shi azaman allurar subcutaneous sau ɗaya-mako-mako, Tirzepatide ya nuna ingantaccen inganci a gwaji na asibiti. Yana inganta mahimmancin sarrafa glycemic kuma yana rage nauyin jiki, sau da yawa ya wuce aikin magunguna a halin yanzu. Bugu da ƙari, an lura da yuwuwar fa'idodin cututtukan zuciya.
Mafi yawan illolin da ake samu sune na gastrointestinal, ciki har da tashin zuciya, gudawa, da amai, wadanda yawanci suna da sauƙi zuwa matsakaici a cikin tsanani kuma suna raguwa akan lokaci.
Gabaɗaya, haɓakar Tirzepatide alama ce ta sabon kan iyaka a cikin maganin cututtukan rayuwa, yana ba da kayan aiki mai ƙarfi don sarrafa duka ciwon sukari da kiba.
Lokacin aikawa: Satumba-01-2025